Share on StockTwits
 

Dechra Pharmaceuticals (LON:DPH)‘s stock had its “hold” rating reiterated by research analysts at Oriel Securities Ltd in a report released on Tuesday, AnalystRatingsNetwork reports. They currently have a GBX 690 ($11.32) price target on the stock. Oriel Securities Ltd’s price target would indicate a potential upside of 1.25% from the stock’s previous close.

DPH has been the subject of a number of other recent research reports. Analysts at Investec downgraded shares of Dechra Pharmaceuticals to an “add” rating in a research note on Monday, January 13th. They now have a GBX 780 ($12.80) price target on the stock, up previously from GBX 778 ($12.76). Separately, analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Dechra Pharmaceuticals in a research note on Monday, January 13th. They now have a GBX 740 ($12.14) price target on the stock. Finally, analysts at N+1 Singer reiterated a “hold” rating on shares of Dechra Pharmaceuticals in a research note on Monday, January 13th. They now have a GBX 740 ($12.14) price target on the stock. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Dechra Pharmaceuticals has a consensus rating of “Hold” and an average price target of GBX 762.86 ($12.52).

Shares of Dechra Pharmaceuticals (LON:DPH) traded up 0.73% during mid-day trading on Tuesday, hitting GBX 692.00. 14,486 shares of the company’s stock traded hands. Dechra Pharmaceuticals has a 52-week low of GBX 633.50 and a 52-week high of GBX 791.50. The stock’s 50-day moving average is GBX 703.0 and its 200-day moving average is GBX 695.. The company’s market cap is £603.1 million.

Dechra Pharmaceuticals PLC (LON:DPH) is an international veterinary pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.